Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss ... the FDA approval of Novo ...

Citing topline data from the trial ... profile in line with incretin-based drugs such as its FDA-approved weight loss therapy, semaglutide, and its rival therapy, Eli Lilly’s (LLY) tirzepatide.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved ... 47% greater relative weight loss compared to Wegovy® (semaglutide).

GLP-1 medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro) are FDA-approved ... to weight loss. GLP-1 medications are highly regulated – they go through years of ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss ... 7.2mg semaglutide in more than 500 patients with obesity and diabetes – STEP UP T2D – with data ...

Lizzo is feeling "Good as Hell" as she celebrates a major milestone in her weight loss journey. The "About Damn Time" singer, 36, shared Saturday on Instagram that she has "reached my weight ...